Sacubitril-valsartan in Patients With Heart Failure With Reduced Ejection Fraction From Rural Tanzania

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

238

Participants

Timeline

Start Date

January 5, 2026

Primary Completion Date

April 30, 2028

Study Completion Date

April 30, 2028

Conditions
Heart Failure
Interventions
DRUG

Sacubitril / Valsartan Oral Tablet

A 36-hour wash-out of ACE inhibitors before initiating ARNI will be done, because of a risk of angioedema if ARNI is started without a wash-out period. The ACE inhibitor or ARB will be switched to sacubitril/valsartan 50mg twice daily (24.3 mg sacubitril, 25.7mg valsartan) for two weeks, increased to 100mg twice daily for three weeks, followed by 200mg twice daily

Trial Locations (1)

Unknown

Heart and Lung Clinic, St Francis Regional Referral Hospital, Ifakara, Tanzania, Ifakara

All Listed Sponsors
collaborator

Ifakara Health Institute (IHI)

UNKNOWN

lead

Martin Rohacek

OTHER